CHEMBL214101 BDBM50189988 Rofecoxib analogue
US11786535, Compound Rofecoxib Rofecoxib BDBM22369 US11478464, Compound Rofecoxib 4-(4-methanesulfonylphenyl)-3-phenyl-2,5-dihydrofuran-2-one CHEMBL122 MK 0966
BDBM50451153 Glucuronide Conjugate Of 5-Hydroxy Rofecoxib CHEMBL2303696
5-Hydroxy Rofecoxib 5-Hydroxy-4-(4-methanesulfonyl-phenyl)-3-phenyl-5H-furan-2-one BDBM50094987 CHEMBL1084
- Yamakawa, N; Suzuki, K; Yamashita, Y; Katsu, T; Hanaya, K; Shoji, M; Sugai, T; Mizushima, T Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity. Bioorg Med Chem 22: 2529-34 (2014)
- Weir, MR; Sperling, RS; Reicin, A; Gertz, BJ Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146: 591-604 (2003)
- Rahim, MA; Rao, PN; Knaus, EE Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 12: 2753-6 (2002)
- Zarghi, A; Praveen Rao, PN; Knaus, EE Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity. Bioorg Med Chem 15: 1056-61 (2006)
- Nicoll-Griffith, DA; Yergey, JA; Trimble, LA; Silva, JM; Li, C; Chauret, N; Gauthier, JY; Grimm, E; Léger, S; Roy, P; Thérien, M; Wang, Z; Prasit, P; Zamboni, R; Young, RN; Brideau, C; Chan, CC; Mancini, J; Riendeau, D Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett 10: 2683-6 (2000)
- Navidpour, L; Amini, M; Shafaroodi, H; Abdi, K; Ghahremani, MH; Dehpour, AR; Shafiee, A Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 16: 4483-7 (2006)
- Habeeb, AG; Praveen Rao, PN; Knaus, EE Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J Med Chem 44: 3039-42 (2001)
- Prasit, P; Wang, Z; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Guay, J; Gresser, M; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Riendeau, D; Rodger, I; Zamboni, R The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9: 1773-8 (1999)
- Smil, DV; Souza, FE; Fallis, AG A general carbometalation, three component coupling strategy for the synthesis of alpha,beta-unsaturated gamma-sultines including thio-rofecoxib, a selective COX-2 inhibitor. Bioorg Med Chem Lett 15: 2057-60 (2005)
- Chan, CC; Boyce, S; Brideau, C; Charleson, S; Cromlish, W; Ethier, D; Evans, J; Ford-Hutchinson, AW; Forrest, MJ; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; O'Neill, GP; Ouellet, M; Patrick, D; Percival, MD; Perrier, H; Prasit, P; Rodger, I Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-60 (1999)
- Zarghi, A; Praveen Rao, PN; Knaus, EE Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 14: 1957-60 (2004)